Suppr超能文献

[牡丹颗粒治疗气虚络瘀证糖尿病周围神经病变的临床综合评价]

[Clinical comprehensive evaluation of Mudan Granules in treatment of diabetic peripheral neuropathy with Qi-deficiency and collateral stagnation syndrome].

作者信息

Zhang Li-Dan, Cui Xin, Liu Fu-Mei, Xie Yan-Ming, Zhang Qiang

机构信息

Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences Beijing 100700, China.

出版信息

Zhongguo Zhong Yao Za Zhi. 2021 Dec;46(23):6078-6086. doi: 10.19540/j.cnki.cjcmm.20210930.501.

Abstract

This study explored the clinical comprehensive evaluation of Mudan Granules, aiming to promote the safe, effective and rational use of Mudan Granules, reflect its clinical value and provide a basis for medical decision-making. The safety, effectiveness, economy, innovation, suitability, accessibility, and characteristics of traditional Chinese medicine of Mudan Granules were combed, and the multi-criteria decision analysis(MCDA) model was used to carry out comprehensive evaluation on each dimension. In terms of safety, multiple sources of evidence showed that the adverse reactions of Mudan Granules mainly involved gastrointestinal system, with controllable safety risk rated as grade B. In terms of effectiveness, Mudan Granules can significantly alleviate the diabetic peripheral neuropathy(Qi-deficiency and collateral stagnation syndrome), limb and trunk numbness, pain and sensory abnormalities and other clinical symptoms, exhibiting positive curative effect rated as grade A. In terms of economy, Mudan Granules combined with Mecobalamin and other conventional western medicines is economical compared with the western medicine alone group, which is supported by sufficient evidence and clear results, rated as grade B. In terms of innovation, Mudan Granules is the only Chinese patent medicine with the indication of benefiting Qi for activating blood circulation and dredging collaterals in the Medicine Catalogue for National Basic Medical Insurance, Industrial Injury Insurance, and Maternity Insurance. It has important clinical innovation and is evaluated as grade A. In the aspect of suitability, Mudan Granules has good suitability in ADR treatment, drug characteristics and usage, and is rated as grade B. In terms of accessibility, Mudan Granules has the price level comparable to that of similar drugs, with good affordability. The resources of medicinal materials for the preparation of Mudan Granules are abundant and available, which is rated grade B. Moreover, Mudan Granules, as a hospital preparation with both functions of tonification and purgation, reflects the combination between syndrome differentiation and disease differentiation as well as the combination between overall and local characteristics, and has prominent Chinese medicine features. According to the above dimensions, we suggest to classify Mudan Granules as a class A preparation which can be directly included the policy results of basic clinical drug administration.

摘要

本研究对牡丹颗粒进行临床综合评价,旨在促进牡丹颗粒的安全、有效、合理使用,体现其临床价值,为医疗决策提供依据。梳理了牡丹颗粒的安全性、有效性、经济性、创新性、适用性、可及性及中医药特色等方面,并采用多准则决策分析(MCDA)模型对各维度进行综合评价。在安全性方面,多源证据表明牡丹颗粒的不良反应主要累及胃肠道系统,安全风险可控,评定为B级。在有效性方面,牡丹颗粒能显著缓解糖尿病周围神经病变(气虚络瘀证)、肢体及躯干麻木、疼痛及感觉异常等临床症状,疗效呈阳性,评定为A级。在经济性方面,牡丹颗粒联合甲钴胺等传统西药与单纯西药组相比具有经济性,证据充分且结果明确,评定为B级。在创新性方面,牡丹颗粒是国家基本医疗保险、工伤保险和生育保险药品目录中唯一具有益气活血通络适应证的中成药,具有重要的临床创新性,评定为A级。在适用性方面,牡丹颗粒在不良反应治疗、药物特性及用法等方面具有良好的适用性,评定为B级。在可及性方面,牡丹颗粒价格水平与同类药品相当,可负担性良好。制备牡丹颗粒的药材资源丰富可得,评定为B级。此外,牡丹颗粒作为一种具有补泻兼施功能的医院制剂,体现了辨证与辨病相结合以及整体与局部相结合的特点,具有突出的中医药特色。根据上述维度,建议将牡丹颗粒列为A类制剂,可直接纳入基本临床用药政策结果。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验